Isocitrate dehydrogenase (IDH) mutation status was included in the WHO 2021 classification of diffuse gliomas, allowing for the differentiation of IDH wild-type glioblastoma from IDH-mutant glioblastoma (8). This evidence concerns the gene IDH3A and glioblastoma.